Table 2.

Patient Demographics and Incidence of Complications in the Three Treatment Groups

	Primary n (%)*	Chemotherapy n (%)*	Chemotherapy and EBRT n (%)*	P Value
Eyes	65 (48.1)	49 (36.3)	20 (14.8)
Patients	65 (48.9)	49 (36.8)	19 (14.3)
Age at enucleation,† yrs	2.3 (0.3–9), 2.7±1.8	1.7 (0.2–9), 1.9±1.5	2.6 (1.4–8.3), 3.1±1.6	0.02
Time, diagnosis to enucleation,† mos	0.2 (0–0.9), 0.13±0.12	3.4 (0–34.3), 5.7±7.8	20.5 (0–125.6), 24.3±21.7	<0.0001
20-mm implant	49 (75.4)	35 (71.4)	7 (35)	0.003
PC-HA	47 (72.3)	30 (61.2)	8 (40)	0.03
Event-free course	57 (87.7)	30 (61.2)	6 (30)	<0.0001
Exposure	7 (10.8)	13 (26.5)	8 (40.0)	0.009
Maximum size,† mm	5.0 (1–11), 5.9±4.0	6 (1–14), 6.8±4.2	8 (2–15), 7.6±4.4	0.73
Time to exposure,† mos	5.0 (1.4–43.3), 11.3±15.0	3.2 (0.9–60.7), 11.7±18.6	1.8 (0.9–7.2), 3.2±2.4	0.42
Contracture	0 (0)	5 (10.2)	11 (55.0)	<0.0001
Extrusion	1 (1.5)	2 (4.1)	0 (0)	0.51
Migration	0 (0)	1 (2.0)	0 (0)	0.42
Pyogenic granuloma	0 (0)	8 (16.3)	1 (5.0)	0.003
Further surgeries	6 (9.2)	11 (22.5)	8 (40.0)	0.006
Exposure resolved	5 (71.4)	9 (81.8)	6 (75.0)	0.87

EBRT = external beam radiotherapy; PC-HA = polymer-coated hydroxyapatite.

Significant differences indicated by bolded P values. External beam radiotherapy alone is not included in the table because only 1 eye was in that group.

^*Unless otherwise indicated.

^†Reported as median (range), mean ± standard deviation.